Potassium News and Research

RSS

PolyMedix completes PMX-30063 Phase 1 exposure-escalation clinical study to treat Staph infections

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, today announced the successful completion of a Phase 1 exposure-escalation clinical study with its synthetic defensin-mimetic antibiotic, PMX-30063.

24 Feb 2011

Tips for heart healthiness

Everyone should know the warning signs for a heart attack -- but according to Dr. Isaac Eliaz, effective prevention requires much more than a list of potential symptoms.

23 Feb 2011

New study: Venus White Pro whitens teeth up to 8.4 shades with virtually no sensitivity

Heraeus Kulzer, LLC, the leader in advancing dental esthetics and overall dental wellbeing, announced today the results of a new study that demonstrates that Venus White Pro whitens teeth up to 8.4 shades with virtually no sensitivity.

21 Feb 2011

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2010.

17 Feb 2011

K-V Pharmaceutical to raise $32 million through private placement

K-V Pharmaceutical Company today announced that it has entered into a definitive agreement with a group of institutional investors to raise approximately $32 million of gross proceeds from a private placement of 9,950,000 shares of its Class A Common Stock at $3.25 per share.

14 Feb 2011

Patients with high blood pressure have benign endocrine tumours in adrenal gland: Research

High blood pressure may in some cases be caused by benign hormone-producing tumours of the adrenal cortex. A joint Swedish-American research effort has now uncovered a genetic cause behind the occurrence of such tumours. The findings were published today in the journal Science.

11 Feb 2011

Scientists discover KCNH2 gene mutation in patients with long QT syndrome

Researchers from the Hospital Virgen de las Nieves of the University of Granada have identified the most frequent mutations in the gene KCNH2 in patients with long QT syndrome.

10 Feb 2011

Circassia acquires global rights to novel topical therapeutic for psoriasis and atopic dermatitis

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that it has acquired the worldwide development and commercialization rights to the novel topical therapeutic for psoriasis and atopic dermatitis, PAP-1. Circassia acquired the rights to the proprietary molecule from Airmid Inc, for an undisclosed upfront sum plus milestone payments and royalties on future product sales.

9 Feb 2011

TREK1 activity offers a key target for fluoxetine and other antidepressant drugs

Using a unique and relatively simple cell-based fluorescent assay they developed, scientists with the U.S. Department of Energy's Lawrence Berkeley National Laboratory and the University of California, Berkeley have identified a means by which fluoxetine, the active ingredient in Prozac, suppresses the activity of the TREK1 potassium channel.

8 Feb 2011

Merck reports GAAP net income of $861 million for 2010

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the fourth quarter of $0.88, which excludes purchase accounting adjustments, restructuring costs and merger-related expenses.

4 Feb 2011

FDA lifts clinical hold on Icagen's IND for ICA-105665 epilepsy drug candidate

Icagen, Inc. today announced that, following a review of data from recently completed clinical studies as well as the Company's proposed protocol for a Phase II clinical trial in patients with treatment resistant epilepsy, the FDA has notified the Company that the clinical hold on Icagen's IND for ICA-105665, a novel orally available small molecule KCNQ potassium channel agonist, has been removed.

3 Feb 2011

Baxter launches OLIMEL emulsion for parenteral nutrition

Baxter International today announced the launch of OLIMEL emulsion for infusion in Canada at the American Society of Parenteral and Enteral Nutrition's Clinical Nutrition Week.

From Baxter International Inc. 31 Jan 2011

Scientists discover key clue that can lead to sudden cardiac deaths

Australian researchers have come one step closer to understanding how the rhythm of the heartbeat is controlled and why many common drugs, including some antibiotics, antihistamines and anti-psychotics, can cause a potentially fatal abnormal heart rhythm.

29 Jan 2011

EMA CHMP issues negative opinion against Biogen Idec's FAMPYRA for multiple sclerosis

Biogen Idec announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion recommending against approval of FAMPYRA to improve walking ability in adult patients with multiple sclerosis (MS) in the European Union. Biogen Idec intends to appeal this opinion and request a re-examination of the decision by the CHMP.

21 Jan 2011

K-V Pharmaceutical provides update on FDA review of NDA for Gestiva

K-V Pharmaceutical Company today issued an update on the status of the U.S. Food and Drug Administration's review of Hologic, Inc.'s New Drug Application for Gestiva as a treatment for the prevention of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.

12 Jan 2011

Best diet aid: Water

If you're like most people, losing those last few holiday pounds is high on your list of to-dos this month. Fortunately, one of the best diet aids is free, abundant and right at your fingertips: water.

12 Jan 2011

New research identifies nutrition inadequacy among Americans

At a time when the country is facing an obesity epidemic, the problem of nutrition inadequacy is often overlooked. Yet, many Americans are overweight and undernourished, concludes a new study called "What America's Missing."

12 Jan 2011

Studies show XIFAXAN 550 mg tablets demonstrate significant relief of global IBS symptoms

Salix Pharmaceuticals, Ltd. today announced the New England Journal of Medicine has published results from TARGET 1 and TARGET 2, the Company's two pivotal Phase 3 efficacy and safety studies of XIFAXAN (rifaximin) 550 mg tablets for the treatment of Irritable Bowel Syndrome without constipation, or Non-C IBS.

6 Jan 2011

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Celgene International Sàrl announced regulatory submissions for its blood cancer therapies REVLIMID (lenalidomide) and ISTODAX (romidepsin).

5 Jan 2011

Hangover tips for the festive season!

A bad hangover usually comes with a variety of symptoms like headaches, fatigue, upset stomach, sweating, nausea, bad taste in the mouth excessive thirst, sensitivity to light etc. This is mainly due to the diuretic effects of alcohol that leaves one dehydrated.

28 Dec 2010

Potassium News and Research

PolyMedix completes PMX-30063 Phase 1 exposure-escalation clinical study to treat Staph infections

Tips for heart healthiness

New study: Venus White Pro whitens teeth up to 8.4 shades with virtually no sensitivity

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

K-V Pharmaceutical to raise $32 million through private placement

Patients with high blood pressure have benign endocrine tumours in adrenal gland: Research

Scientists discover KCNH2 gene mutation in patients with long QT syndrome

Circassia acquires global rights to novel topical therapeutic for psoriasis and atopic dermatitis

TREK1 activity offers a key target for fluoxetine and other antidepressant drugs

Merck reports GAAP net income of $861 million for 2010

FDA lifts clinical hold on Icagen's IND for ICA-105665 epilepsy drug candidate

Baxter launches OLIMEL emulsion for parenteral nutrition

Scientists discover key clue that can lead to sudden cardiac deaths

EMA CHMP issues negative opinion against Biogen Idec's FAMPYRA for multiple sclerosis

K-V Pharmaceutical provides update on FDA review of NDA for Gestiva

Best diet aid: Water

New research identifies nutrition inadequacy among Americans

Studies show XIFAXAN 550 mg tablets demonstrate significant relief of global IBS symptoms

Celgene announces regulatory submissions for blood cancer therapies REVLIMID and ISTODAX

Hangover tips for the festive season!

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News